Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1379-1382

  Linnet, Kristian ^a   Olesen, Ole V ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; COMPLEMENTARY DNA; CYTOCHROME P450; OXIDE;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER METABOLISM; PRIORITY JOURNAL; SIMULATION;

CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME ACTIVATION; HUMANS; MICROSOMES, LIVER; SUBSTRATE SPECIFICITY;

EID: 0031434742     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. L. Bertilsson and M.-L. Dahl: Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5, 200-223 (1996).
2. S. C. Edge, J. S. Markowitz, and C. L. Devane: Clozapine drug-drug interactions: a review of the literature. Hum. Psychopharmacol. 12, 5-20 (1997).
3. M. J. Byerly and C. L. deVane: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 16, 177-187 (1996).
4. M. Pirmohamed, D. Williams, S. Madden, E. Templeton, and B. K. Park: Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272, 984-990 (1995).
5. V. Fischer, B. Vogels, G. Maurer, and R. E. Tynes: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260, 1355-1360 (1992).
6. L. Bertilsson, J. A. Carrillo, M.-L. Dahl, A. Llerena, C. Alm, U. Bondesson, L. Lindström, I. R. de la Rubia, S. Ramos, and J. Benitez: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38, 471-473 (1994).
7. M.-L. Dahl, A. Llerena, U. Bondesson, L. Lindström, and L. Bertilsson: Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 37, 71-74 (1994).
8. R. T. Coutts, P. Su, and G. B. Baker: Involvement of CYP2D6, CYP3A4, and other cytochrome P450 isozymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Methods 31, 177-186 (1994).
9. O. V. Olesen and K. Linnet: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P450 isozymes. Drug Metab. Dispos. 25, 740-744 (1997).
10. U. Fuhr, J. Doehmer, N. Battula, C. Wölfer, C. Kudla, Y. Keita, and A. H. Staib: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol. 43, 225-235 (1992).
11. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, and R. I. Shader: N-Demethylation of amitriptyline in vitro: role of cytochrome P450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275, 592-597 (1995).
12. T. Leemann, C. Transon, and P. Dayer: Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Science (Wash. D. C.) 52, 29-34 (1993).D. C.
13. S. D. Hall, F. P. Guengerich, R. A. Branch, and G. R. Wilkinson: Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther. 240, 216-222 (1987)
14. M.-L. Dahl, C. Nordin, and L. Bertilsson: Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther. Drug Monit. 13, 189-194 (1991).
15. R. B. Kim, D. O'Shea, and G. R. Wilkinson: Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57, 645-655 (1995).
16. J. Schmider, D. J. Greenblatt, L. L. von Moltke, and R. I. Shader: Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J. Clin. Psychopharmacol. 16, 267-272 (1996).
17. T. Shimada, Y. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P 450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
18. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
19. F. Centorrino, R. J. Baldessarini, J. C. Kando, F. R. Frankenburg, S. A. Volpicelli, and J. G. Flood: Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J. Clin. Psychopharmacol. 14, 119-125 (1994).
20. O. V. Olesen, K. Thomsen, P. N. Jensen, C. H. Wulff, N.-A. Rasmussen, C. Refshammer, J. Sørensen, M. Bysted, J. Christensen, and R. Rosenberg: Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 117, 371-378 (1995).
21. R. C. Baselt and R. H. Cravey (eds.): Clozapine. In "Disposition of Toxic Drugs and Chemicals in Man," pp. 182-184. Chemical Toxicology Institute, Foster City, CA, 1995.
22. C. Haring, U. Meise, C. Humpel, A. Saria, W. W. Fleischhacker, and H. Hinterhuber: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 99, S38-S40 (1989).
23. M. Jerling, L. Lindström, U. Bondesson, and L. Bertilsson: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 16, 368-374 (1994).
24. M. Hasegawa, R. Gutierrez-Esteinou, L. Way, and H. Y. Meltzer: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 13, 383-390 (1993).
25. Z.-H. Xu, H.-G. Xie, and H.-H. Zhou: In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br. J. Clin. Pharmacol. 42, 518-521 (1996).
26. H. K. Crewe, M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock: The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 45, 1211-1214 (1992).
27. L. Funderburg, J. Vertrees, J. True, and A. Miller: Seizure following addition of erythromycin to clozapine therapy. Am. J. Psychiatry 151, 1840-1841 (1994).
28. L. G. Cohen, S. Chesley, L. Eugenio, J. G. Flood, J. Fish, and D. Goff: Erythromycin-induced clozapine toxic reaction. Arch. Intern. Med. 156, 675-677 (1996).
29. Y. F. Cheng, T. Lundberg, U. Bondesson, L. Lindström, and J. Gabrielsson: Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol. 34, 445-449 (1988).
30. E. Skjelbo, K. Brøsen, J. Hallas, and L. F. Gram: The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49, 18-23 (1991).
31. U. Breyer-Pfaff, B. Pfandl, K. Nill, E. Nusseer, C. Monney, M. Jonzier-Perey, D. Baettig, and P. Baumann: Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther. 52, 350-358 (1992).
32. P. Ghahramani, S. W. Ellis, M. S. Lennard, L. E. Ramsay, and G. T. Tucker: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 43, 137-144 (1997).